Sharp Services, a global leader in pharmaceutical packaging and clinical trial supply, has announced a $100 million investment across its US and European facilities to meet growing demand for injectable and oral solid dose (OSD) packaging, as well as sterile manufacturing.
The investment covers several strategic sites, including new sterile fill/finish capacity in Lee, Massachusetts, and expanded injectable assembly and packaging lines in the Netherlands, Belgium, Allentown and Macungie, Pennsylvania.
In the US, Sharp’s Allentown site will gain new syringe assembly, vial labeling and high-speed cartoning lines, alongside new bottling and pouching equipment for OSD products. These additions complement a $20 million expansion in Macungie, focused on autoinjector and pen assembly.
Meanwhile, the Bethlehem facility is boosting its clinical capabilities with new cold-chain storage, capsule filling and blistering lines, while Lee, MA, will see the installation of a fourth isolator-based sterile filling line with lyophilization, supported by a $28 million investment.
In Europe, the Netherlands site is set to enhance GMP capacity for vial labeling and injectables packaging by 2026, and Belgium will add significant cold-chain storage and a syringe blistering suite.
According to Kevin Orfan, President & CEO, these multi-site investments reflect Sharp’s “ongoing commitment to support the evolving needs of pharma and biopharma clients,” reinforcing its role as a trusted partner from clinical development to commercial supply.
With nine GMP facilities worldwide and more than 2,500 employees, Sharp continues to expand its footprint in pharmaceutical services to help bring critical medicines to patients faster and more efficiently.